Abstract：
In Japan, the Pharmaceutical and Medical Device Act was amended in December 2019, and now requires pharmacists to follow-up on patients during treatment. Although there have been some studies on the effectiveness of follow-ups by pharmacists, there are no reports on the status of implementation in clinical practice. We conducted a nationwide survey on follow-up care to investigate the actual situation. We randomly selected 10% of community pharmacies in each prefecture and conducted a survey. We built a web-based system for the collection of basic information on the pharmacies and follow-up cases. A total of 561 pharmacies were pre-entered. Of these, 110 pharmacies (19.6%) reported 326 follow-up cases. Information was provided to doctors in 129 cases (39.6%), of which prescription proposals were made in 10 (7.8%) instances. The follow-up implementation rate based on the number of prescriptions dispensed was estimated to be 0.84% (95% confidence interval: 0.76-0.94%). This study revealed the status of follow-ups in clinical practice. Pharmacists can contribute to the optimization of drug treatment by providing follow-up information to doctors and making prescription proposals.
摘要：
在日本,2019年12月修订了《制药和医疗器械法》,现在要求药剂师在治疗期间对患者进行随访.虽然有一些关于药剂师随访效果的研究，没有关于临床实践实施情况的报告。我们进行了全国范围的后续护理调查，以调查实际情况。我们在每个州随机抽取了10%的社区药店，并进行了调查。我们建立了一个基于网络的系统，用于收集药房和随访病例的基本信息。共有561家药房预先登记。其中,110家药店（19.6%）报告了326例随访病例。129例(39.6%)向医生提供了信息，其中10例(7.8%)提出处方建议。基于处方数量的随访执行率估计为0.84%(95%置信区间:0.76-0.94%)。这项研究揭示了临床实践中的随访状况。药剂师可以通过向医生提供后续信息并提出处方建议来为药物治疗的优化做出贡献。
